





Supplementary Figure 1

Bevacizumab group



Sunitinib group



Bevacizumab group

A	sPD-L1 < 0.1 ng/ml	sPD-L1 > 0.1 ng/ml	p value
Number	25	12	
Age	58.1	56	ns
Sex			
Female	5 (20%)	10 (17.4%)	ns
Male	20 (80%)	2 (82.6%)	
pT			
1/2	9 (42.9%)	3 (33.3%)	ns
3/4	12 (57.1%)	6 (66.7%)	
x	4	3	
pN			
0	21 (84%)	9 (75%)	ns
≥ 1	4 (16%)	3 (25%)	
pM			
0	15 (60%)	9 (75%)	ns
1	10 (40%)	3 (25%)	
Stage			
I+II	7 (33.3%)	2 (20%)	ns
III+IV	14 (66.7%)	8 (80%)	
x	4	2	
Fuhrman grade			
1/2	6 (28.6%)	1 (10%)	ns
3/4	15 (71.4%)	9 (90%)	
x	4	2	
PFS (months)	11.4	7.7	ns
OS (months)	<36	19.3	ns

Supplementary Table 1

Bevacizumab group

A	sPD-1 < 1.67 ng/ml	sPD-1 > 1.67 ng/ml	p value
Number	29	8	
Age	58	54.6	ns
Sex			ns
Female	5 (17.2%)	2 (25%)	
Male	24 (82.8%)	6 (75%)	
pT			ns
1/2	10 (43.5%)	2 (28.6%)	
3/4	13 (56.5%)	5 (71.4%)	
x	6	1	
pN			ns
0	25 (86.2%)	5 (62.5%)	
≥ 1	4 (13.8%)	3 (37.5%)	
pM			ns
0	17 (58.6%)	7 (87.5%)	
1	12 (41.4%)	1 (12.5%)	
Stage			ns
I+II	7 (30.4%)	2 (25%)	
III+IV	16 (69.6%)	6 (75%)	
x	6	0	
Fuhrman grade			ns
1/2	6 (25%)	1 (14.3%)	
3/4	18 (75%)	6 (85.7%)	
x	5	1	
PFS (months)	11.5	11.9	ns
OS (months)	<36	22.7	ns

Supplementary Table 2